摘要
目的分析早期应用阿托伐他汀对急性冠状动脉综合征(ACS)患者炎症反应的影响,为阿托伐他汀治疗ACS提供理论依据。方法计算机检索中国知网、万方数据库、维普全文数据库、Pub Med、Highwire和Google学术数据库等关于阿托伐他汀治疗ACS的随机对照试验,对符合质量标准的研究结果进行Meta分析。统计学分析采用Rev Man5.2版软件。结果与对照组比较,阿托伐他汀治疗组患者高敏C反应蛋白明显降低,[MD=-6.02,95%CI(-7.74,-4.30)],肿瘤坏死因子-α和白细胞介素-6均明显下降[MD=-8.18,95%CI(-15.4,-0.95);SMD=-1.34,95%CI(-1.83,-0.84)]。大剂量阿托伐他汀比小剂量阿托伐他汀的抗炎效果更好,[MD=-1.88,95%CI(-3.64,-0.12)]。结论阿托伐他汀能有效改善ACS患者炎症反应。
Objective To analyze anti-inflammatory effect of early application of atorvastatin in patients with acute coronary syndromes（ ACS）,and provide theoretical basis for ACS treatment by atorvastatin. Methods Literature was searched for randomized controlled trials about atorvastatin in the treatment of ACS in CNKI,Wanfang,VIP,Pub Med,Highwire and Google Scholar databases.Meta-analysis was conducted on the outcomes of the trials that met the inclusion criteria. Rev Man 5.2 software was applied for statistical analysis. Results The results showed that atorvastatin significantly ameliorated the inflammation reaction as evidenced by a decrease of high sensitivity C reactive protein（ hs-CRP） compared with the control group[MD =-6.02,95% CI（-7.74,-4.30） ].The levels of TNF-α[MD =-8.18,95% CI（-15.4,- 0.95） ] and IL-6[SMD =- 1.34,95% CI（-1.83,-0.84） ]were also decreased after atorvastatin treatment. The anti-inflammatory effect of atorvastatin at high-dose was better than that at low-dose[MD =- 1. 88,95% CI（- 3. 64,- 0. 12） ]. Conclusion Atorvastatin can effectively ameliorate the inflammatory reaction in patients with ACS in China.
出处
《医药导报》
CAS
2016年第1期83-89,共7页
Herald of Medicine
基金
湖南省自然科学基金资助项目(14JJ5016)
